The FDA has approved Onglyza, a once-daily treatment for type 2 diabetes to be taken in combination with diet and exercise. Onglyza, manufactured by Bristol-Myers Squibb, was tested in diabetes patients at relatively low risk of heart disease. The FDA approval requires Bristol-Myers Squibb to conduct a postmarketing study to evaluate the drug’s heart safety in higher-risk patients.